Doroshow J H, Metz M Z, Matsumoto L, Winters K A, Sakai M, Muramatsu M, Kane S E
Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010, USA.
Cancer Res. 1995 Sep 15;55(18):4073-8.
In the experiments, we examined the ability of a retroviral vector, pHaMASV, to encode two potential chemoprotective genes on separate transcription units. We previously described the pHaMSV vector, which includes the human MDR1 gene as a selectable marker and chemoprotective gene, plus an internal SV40 promoter for expressing a second heterologous gene along with MDR1 [M. E. Metz, D. M. Best, and S. E. Kane. Virology, 208: 634-643, 1995]. To test the ability of this vector to deliver two therapeutic genes simultaneously, the cDNA for human glutathione S-transferase pi (GST pi, the most abundant member of the glutathione S-transferase family in human tumor cells) was inserted into pHaMASV, and this plasmid was transfected into ecotropic packaging cells. The resulting pHaMASV.GST pi ecotropic retrovirus, which was produced at a titer of 2 x 10(6) colony-forming units/ml, was used to transduce NIH 3T3 cells. After initial selection in 60 ng/ml colchicine, a population of transduced cells was exposed to stepwise increasing colchicine concentrations to select for amplified expression of MDR1. As MDR1 expression increased, the expression of GST pi increased in concert, as demonstrated by Northern analysis, Western analysis, and measurement of glutathione S-transferase activity. Transduced cells growing in 1280 ng/ml colchicine had about 3-fold higher total glutathione S-transferase activity than nontransduced cells and 2.5-fold higher activity than transduced cells growing in 60 ng/ml colchicine. Northern hybridizations demonstrated a 3-5-fold increase in both the full-length retroviral message encoding MDR1 and the subgenomic mRNA encoding GST pi after amplification of resistance from 60 to 1280 ng/ml colchicine. The cytotoxic effects of several xenobiotics were evaluated in NIH 3T3 cells transfected with MDR1 (3T3.MDR) or transduced with the MDR1-GST pi retrovirus (3T3.GST640 or 3T3.GST1280) to evaluate the ability of our vector to produce a spectrum of drug resistances specific for the genes expressed. 3T3.MDR and 3T3.GST1280 cells expressing equivalent levels of MDR1 had identical levels of resistance to doxorubicin or colchicine. These results suggest that GST pi expression did not contribute to doxorubicin resistance in this model system. However, 3T3.GST640 cells were about 4-fold resistant to ethacrynic acid and 1-chloro-2,4-dinitrobenzene compared to cells expressing MDR1 alone, consistent with the ability of GST pi to conjugate both of these cytotoxins. Increases in drug resistance paralleled increases in gene-specific mRNA and recombinant protein levels in all cases.4+ chemotherapy.
在实验中,我们检测了逆转录病毒载体pHaMASV在不同转录单元上编码两个潜在化学保护基因的能力。我们之前描述过pHaMSV载体,它包含人类多药耐药基因1(MDR1)作为选择标记和化学保护基因,以及一个内部SV40启动子,用于与MDR1一起表达第二个异源基因[M. E. 梅茨、D. M. 贝斯特和S. E. 凯恩。《病毒学》,208: 634 - 643,1995]。为了测试该载体同时递送两个治疗基因的能力,将人类谷胱甘肽S - 转移酶pi(GST pi,人类肿瘤细胞中谷胱甘肽S - 转移酶家族中最丰富的成员)的cDNA插入pHaMASV,并将该质粒转染到嗜亲性包装细胞中。产生的滴度为2×10⁶集落形成单位/毫升的pHaMASV.GST pi嗜亲性逆转录病毒用于转导NIH 3T3细胞。在60纳克/毫升秋水仙碱中进行初始选择后,将一群转导细胞暴露于逐步增加的秋水仙碱浓度下,以选择MDR1的扩增表达。随着MDR1表达增加,GST pi的表达也相应增加,这通过Northern分析、Western分析以及谷胱甘肽S - 转移酶活性测定得以证明。在1280纳克/毫升秋水仙碱中生长的转导细胞的总谷胱甘肽S - 转移酶活性比未转导细胞高约3倍,比在60纳克/毫升秋水仙碱中生长的转导细胞高2.5倍。Northern杂交显示,在秋水仙碱抗性从60纳克/毫升扩增到1280纳克/毫升后,编码MDR1的全长逆转录病毒信使RNA和编码GST pi的亚基因组mRNA均增加了3 - 5倍。在转染了MDR1的NIH 3T3细胞(3T3.MDR)或用MDR1 - GST pi逆转录病毒转导的细胞(3T3.GST640或3T3.GST1280)中评估了几种异生物质的细胞毒性作用,以评估我们的载体产生针对所表达基因的一系列耐药性的能力。表达等效水平MDR1的3T3.MDR和3T3.GST1280细胞对阿霉素或秋水仙碱具有相同水平的抗性。这些结果表明,在该模型系统中GST pi表达对阿霉素抗性没有贡献。然而,与仅表达MDR1的细胞相比,3T3.GST640细胞对依他尼酸和1 - 氯 - 2,4 - 二硝基苯具有约4倍的抗性,这与GST pi结合这两种细胞毒素的能力一致。在所有情况下,耐药性的增加与基因特异性mRNA和重组蛋白水平的增加平行。4 + 化疗。